

## ERYTECH announces its financial calendar for 2014

---

**Lyon (France), January 20<sup>th</sup>, 2014** – ERYTECH Pharma (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces its financial calendar for 2014.

<b>January 27, 2014:</b>	Publication of Q4 and full year 2013 revenues (after market)
<b>April 29, 2014:</b>	Publication of 2013 annual results (after market)
<b>May 15, 2014:</b>	Publication of Q1 2014 revenues (after market)
<b>June 17, 2014:</b>	Annual shareholders' meeting
<b>July 16, 2014:</b>	Publication of Q2 2014 revenues (after market)
<b>September 2, 2014:</b>	Publication of H1 2014 results (after market)
<b>November 4, 2014:</b>	Publication of Q3 2014 revenues (after market)

Beyond these periodicals, investors are invited to consult the website of the company ([www.erytech.com](http://www.erytech.com)) where information is regularly updated. All corporate and financial information on the company is available on the company's website, in the Investors' section.

### **About ERYTECH and GRASPA®:** [www.erytech.com](http://www.erytech.com)

Founded in Lyon in 2004, ERYTECH is a French biopharmaceutical company providing new prospects for cancer patients, particularly those with acute leukemia and selected solid tumors.

Every year about 50,000 patients are diagnosed with Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML), the two forms of acute leukemia. Today, for about 80% of these patients, mainly adults and relapsing patients, there is no adequate solution due to the toxicity of existing treatments. By encapsulating the asparaginase enzyme in red blood cells, ERYTECH has developed GRASPA®, an original and effective treatment that targets leukemia cells through "starvation" while significantly reducing the side effects for patients, and allowing all patients to be treated, even the most fragile ones, representing a market opportunity of more than EUR 1 billion. GRASPA® is currently completing Phase III clinical development in Acute Lymphoblastic Leukemia (ALL) and is in Phase IIb clinical trial in Acute Myeloid Leukemia (AML) in Europe. The product received FDA clearance to start clinical development in ALL in the USA. ERYTECH has concluded distribution partnership agreements for Europe with Orphan Europe (Recordati Group), and with TEVA for Israel. The company is also developing other indications in solid tumors and certain orphan indications outside oncology. ERYTECH has its own GMP-approved and operational manufacturing site.

*ERYTECH is listed on Euronext regulated market in Paris. (ISIN code: FR0011471135, ticker: ERYP) and is part of the CAC Healthcare, CAC Pharm. & Bio and Next Biotech indexes.*

## CONTACTS

### ERYTECH

**Gil Beyen**

*Chairman and CEO*

**Pierre-Olivier Goineau**

*Vice President and COO*

Tel: +33 4 78 74 44 38

[investors@erytech.com](mailto:investors@erytech.com)

*NewCap.*

**Julien Perez / Emmanuel Huynh**

Investor and press relations

Tel: +33 1 44 71 98 52

[erytech@newcap.fr](mailto:erytech@newcap.fr)

